35 results on '"Santabarbara, G."'
Search Results
2. SO-26 Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study
- Author
-
De Stefano, A., Giuliani, F., Nasti, G., Montesarchio, V., Santabarbara, G., Leo, S., Malapelle, U., Rosati, G., Lolli, I., Tamburini, E., Colombo, A., Santini, D., Silvestro, L., Leone, A., Vitagliano, C., Troncone, G., Sobrero, A., Giannarelli, D., Budillon, A., and Avallone, A.
- Published
- 2023
- Full Text
- View/download PDF
3. A rare case of extraovarian primary peritoneal carcinoma in a 72 year-old woman
- Author
-
Fei L, Romano G, Trapani V, De Vita F, Santabarbara G, Cimmino M, and Moccia F
- Subjects
Geriatrics ,RC952-954.6 - Published
- 2010
- Full Text
- View/download PDF
4. 397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study
- Author
-
Martinelli, E., primary, Martini, G., additional, Troiani, T., additional, Pietrantonio, F., additional, Avallone, A., additional, Normanno, N., additional, Nappi, A., additional, Maiello, E., additional, Falcone, A., additional, Santabarbara, G., additional, Pinto, C., additional, Santini, D., additional, Ciardiello, D., additional, Terminiello, M., additional, Borrelli, C., additional, Napolitano, S., additional, Renato, D., additional, Famiglietti, V., additional, Esposito, L., additional, and Ciardiello, F., additional
- Published
- 2020
- Full Text
- View/download PDF
5. Neo-adjuvant and adjuvant chemotherapy of gastric cancer
- Author
-
De Vita, F., Giuliani, F., Galizia, G., Belli, C., Aurilio, G., Santabarbara, G., Ciardiello, F., Catalano, G., and Orditura, M.
- Published
- 2007
6. 668TiP - Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon
- Author
-
Martinelli, E., Troiani, T., Cardone, C., Ciardiello, D., Zanaletti, N., Borrelli, C., Terminiello, M., Avallone, A., Falcone, A., Maiello, E., Bordonaro, R., Santini, D., Garufi, C., Pietrantonio, F., Pinto, C., Santabarbara, G., Normanno, N., and Ciardiello, F.
- Published
- 2019
- Full Text
- View/download PDF
7. Novel immunotherapy in the treatment of advanced non-small cell lung cancer
- Author
-
Santabarbara, G., primary, Maione, P., additional, Rossi, A., additional, Palazzolo, G., additional, and Gridelli, C., additional
- Published
- 2016
- Full Text
- View/download PDF
8. Metastatic Renal Cell Carcinoma (Mrcc) Treated with Targeted Therapies (Tt) in the Community Setting: an Italian Survey on 1238 Pts
- Author
-
Pasini, F., primary, Fraccon, A.P., additional, Zustovich, F., additional, Sacco, C., additional, Valcamonico, F., additional, Donati, D., additional, Durante, E., additional, Sorarù, M., additional, Nicodemo, M., additional, Cengarle, R., additional, Randisi, P., additional, Ogliosi, C., additional, Bernardi, D., additional, Ciccarese, C., additional, Zanon, S., additional, Martellucci, I., additional, Falco, I., additional, Mucciarini, C., additional, Mandarà, M., additional, and Santabarbara, G., additional
- Published
- 2014
- Full Text
- View/download PDF
9. A rare case of extraovarian primary peritoneal carcinoma in a 72 year-old woman
- Author
-
Moccia, F, primary, Cimmino, M, additional, Santabarbara, G, additional, De Vita, F, additional, Trapani, V, additional, Romano, G, additional, and Fei, L, additional
- Published
- 2010
- Full Text
- View/download PDF
10. Serum Vascular Endothelial Growth Factor (VEGF) Levels Correlate with Tumor VEGF and p53 Overexpression in Endocrine Positive Primary Breast Cancer
- Author
-
Iovino, F., primary, Ferraraccio, F., additional, Orditura, M., additional, Antoniol, G., additional, Morgillo, F., additional, Cascone, T., additional, Diadema, M. R., additional, Aurilio, G., additional, Santabarbara, G., additional, Ruggiero, R., additional, Belli, C., additional, Irlandese, E., additional, Fasano, M., additional, Ciardiello, F., additional, Procaccini, E., additional, Lo Schiavo, F., additional, Catalano, G., additional, and De Vita, F., additional
- Published
- 2008
- Full Text
- View/download PDF
11. 841P - Metastatic Renal Cell Carcinoma (Mrcc) Treated with Targeted Therapies (Tt) in the Community Setting: an Italian Survey on 1238 Pts
- Author
-
Pasini, F., Fraccon, A.P., Zustovich, F., Sacco, C., Valcamonico, F., Donati, D., Durante, E., Sorarù, M., Nicodemo, M., Cengarle, R., Randisi, P., Ogliosi, C., Bernardi, D., Ciccarese, C., Zanon, S., Martellucci, I., Falco, I., Mucciarini, C., Mandarà, M., and Santabarbara, G.
- Published
- 2014
- Full Text
- View/download PDF
12. 126P From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis.
- Author
-
Pusceddu, V., Pretta, A., Palma, V., Dettori, M., Ziranu, P., Palmas, E., Moledda, G., Sanna, G., Codipietro, C., Donisi, C., Rizzo, D., D'Agata, A.P., Balconi, F., Mariani, S., Lai, E., Puzzoni, M., Mascia, L., Santabarbara, G., and Scartozzi, M.
- Subjects
- *
RECTAL cancer , *TUMOR grading , *RETROSPECTIVE studies , *TUMORS - Published
- 2023
- Full Text
- View/download PDF
13. Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
- Author
-
Erika Martinelli, Teresa Troiani, Lucia Esposito, Nicola Normanno, Davide Ciardiello, Carmine Pinto, Evaristo Maiello, Chiara Cremolini, Tiziana Latiano, Vincenzo Famiglietti, Giuseppe Santabarbara, Giulia Martini, Antonio Avallone, Stefania Napolitano, Fortunato Ciardiello, Filippo Pietrantonio, Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Normanno, N., Avallone, A., Latiano, T., Maiello, E., Pietrantonio, F., Cremolini, C., Santabarbara, G., Pinto, C., Troiani, T., Martinelli, E., Ciardiello, F., and Martini, G.
- Subjects
Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,Gastroenterology ,Article ,Refractory ,Statistical significance ,Internal medicine ,Medicine ,RC254-282 ,Chemotherapy ,Univariate analysis ,Cetuximab ,business.industry ,Hazard ratio ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,skin toxicity ,Rechallenge anti‐EGFR ,Oncology ,mCRC ,rechallenge anti-EGFR ,Biomarker (medicine) ,Immunotherapy ,MCRC ,Skin toxicity ,immunotherapy ,business ,medicine.drug - Abstract
The single-arm phase II CAVE mCRC trial evaluated the combination of cetuximab plus avelumab as rechallenge strategy in RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients, with clinical response to first-line anti-EGFR-based chemotherapy, who progressed and received a subsequent line of therapy. The correlation of skin toxicity (ST) and different clinico-molecular variables with overall survival (OS), progression-free survival (PFS) and response rate (RR) was assessed at univariate and multivariate analysis. A total of 33/77 (42.9%) patients experienced grade 2–3 ST and displayed median OS (mOS) of 17.8 months (CI 95%, 14.9–20.6), whereas 44/77 (57.1%) patients with grade 0–1 ST exhibited mOS of 8.2 months (CI 95%, 5.5–10.9), (hazard ratio (HR), 0.51, CI 95%, 0.29–0.89, p = 0.019). Median PFS (mPFS) was 4.6 months (CI 95%, 3.4–5.7) in patients with grade 2–3 ST, compared to patients with grade 0–1 ST with mPFS of 3.4 months (CI 95%, 2.7–4.1, HR, 0.49, CI 95%, 0.3–0.8, p = 0.004). Grade 2–3 ST (HR, 0.51, p = 0.019) and RAS/BRAF/EGFR WT circulating tumor DNA (ctDNA) (HR, 0.50, CI 95%, 0.27–0.9, p = 0.019) had a statistically significant effect on OS at univariate analysis. At the multivariate analysis, RAS/BRAF/EGFR WT ctDNA status maintained statistical significance (HR, 0.49, p = 0.023), whereas there was a trend towards ST grade 2–3 (HR, 0.54, CI 95%, 0.29–1.01, p = 0.054). Skin toxicity is a promising biomarker to identify patients with mCRC that could benefit of anti-EGFR rechallenge.
- Published
- 2021
14. Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial
- Author
-
Teresa Troiani, Federica Morano, M. Terminiello, Giuseppe Santabarbara, Evaristo Maiello, Davide Ciardiello, Carmine Pinto, Anna Nappi, Erika Martinelli, Vincenzo Famiglietti, Claudia Cardone, Alessandra Di Liello, C. Borrelli, Chiara Cremolini, Antonio Avallone, Filippo de Braud, Stefania Napolitano, N. Zanaletti, Daniela Renato, Lucia Esposito, Daniele Santini, Filippo Pietrantonio, Tiziana Latiano, Giulia Martini, Pietro Paolo Vitiello, Nicola Normanno, Francesca Marrone, Daniele Rossini, Fortunato Ciardiello, Alfredo Falcone, Martinelli, E., Martini, G., Famiglietti, V., Troiani, T., Napolitano, S., Pietrantonio, F., Ciardiello, D., Terminiello, M., Borrelli, C., Vitiello, P. P., De Braud, F., Morano, F., Avallone, A., Normanno, N., Nappi, A., Maiello, E., Latiano, T., Falcone, A., Cremolini, C., Rossini, D., Santabarbara, G., Pinto, C., Santini, D., Cardone, C., Zanaletti, N., Di Liello, A., Renato, D., Esposito, L., Marrone, F., and Ciardiello, F.
- Subjects
Male ,Neuroblastoma RAS viral oncogene homolog ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,Cetuximab ,Antibodies, Monoclonal, Humanized ,medicine.disease_cause ,Gastroenterology ,Proto-Oncogene Proteins p21(ras) ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Clinical endpoint ,Humans ,Adverse effect ,Original Investigation ,Chemotherapy ,business.industry ,Hazard ratio ,Middle Aged ,medicine.disease ,Oncology ,Female ,KRAS ,Colorectal Neoplasms ,business ,medicine.drug - Abstract
IMPORTANCE: Rechallenge therapy with anti–epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti–EGFR-based first-line treatment. The association of treatment with cetuximab plus avelumab with overall survival (OS) may be worthy of investigation in this setting. OBJECTIVE: To assess the efficacy and safety of cetuximab rechallenge therapy plus avelumab. DESIGN, SETTING, AND PARTICIPANTS: This single-arm, multicenter phase 2 trial enrolled patients from August 2018 to February 2020. Eligible patients with RAS WT mCRC had a complete or partial response to first-line chemotherapy plus anti-EGFR drugs, developed acquired resistance, and failed second-line therapy. Baseline circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S492R mutation analysis was done. INTERVENTIONS: Patients received avelumab (10 mg/kg every 2 weeks) and cetuximab (400 mg/m(2) and, subsequently, 250 mg/m(2) weekly) until disease progression or unacceptable toxic effects. MAIN OUTCOMES AND MEASURES: The primary end point was OS. Secondary end points were progression-free survival (PFS), overall response rate (ORR), and safety. RESULTS: Seventy-seven patients were enrolled (42 men, 35 women; median age, 63 years); 71 had microsatellite stable tumors (MSS), 3 microsatellite instability-high tumors (MSI-H), 3 unknown. The study met the primary end point, with median OS (mOS) of 11.6 months (95% CI, 8.4-14.8 months). Median PFS (mPFS) was 3.6 months (95% CI, 3.2-4.1 months). Common grade-3 adverse events were cutaneous eruption, 11 (14%), and diarrhea, 3 (4%). For 67 of 77 (87%) patients, baseline analysis of plasma circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S492R variations was feasible. Forty-eight patients had WT disease, whereas 19 had mutations. Patients with RAS/BRAF WT ctDNA had mOS of 17.3 months (95% CI, 12.5-22.0 months) compared with 10.4 months (95% CI, 7.2-13.6 months) in patients with mutated ctDNA (hazard ratio [HR], 0.49; 95% CI, 0.27-0.90; P = .02). The mPFS was 4.1 months (95% CI, 2.9-5.2 months) in RAS/BRAF WT patients compared with 3.0 months (95% CI, 2.6-3.5 months) in patients with mutated ctDNA (HR, 0.42; 95% CI, 0.23-0.75; P = .004). CONCLUSIONS AND RELEVANCE: The findings of this single-arm phase 2 trial suggest that cetuximab plus avelumab is an active, well tolerated rechallenge therapy in RAS WT mCRC. Plasma ctDNA analysis before treatment may allow selection of patients who could benefit. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04561336
- Published
- 2021
15. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists
- Author
-
Sara Parola, Diletta Cavallero, Pietro De Placido, Rossella Di Franco, Francesca Zacchi, Giacomo Cartenì, Sabino De Placido, Claudia von Arx, Alice Rossi, Fernanda Picozzi, Pasquale Rescigno, Laura Attademo, Giovannella Palmieri, Carminia Maria Della Corte, Fabiana Vitiello, Anna Russo, Lucia Nappi, Michele Aieta, Alessia Mennitto, Fabiana Napolitano, Marco Messina, Giuseppe Buono, Valeria Merz, Marco De Felice, Stefano De Falco, Immacolata Paciolla, Irene De Santo, Dario Trapani, Antonio M. Grimaldi, Paolo Tarantino, Alessandro Morabito, Tortora Vincenzo, Stefano Pepe, Giuseppe Palmieri, Antonietta Fabbrocini, Diana Giannarelli, Alfonso De Stefano, Sabrina Vari, Cesare Gridelli, Vittorio Riccio, Angelica Petrillo, Martina Pagliuca, Giuseppe Calderoni, Margaret Ottaviano, Vincenza Conteduca, Michela Lia, Giuseppe Santabarbara, Ester Simeone, Valentina Borzillo, Francesca Caputo, Mario Rosanova, Marcello Curvietto, Pasquale Assalone, Brigitta Mucci, Raffaele Conca, Vito Vanella, Francovito Piantedosi, Vincenzo Montesarchio, Erica Pietroluongo, Lucia Festino, Federica Tomei, Vincenzo Di Lauro, Bruno Daniele, Caterina Vivaldi, Andrea Zivi, Veronica Prati, Pasqualina Giordano, Luisa Piccin, Francesco Bloise, Massimiliano Spada, Jole Ventriglia, Davide Bosso, Alessandro Marco Minisini, Massimiliano Salati, Monica Milano, Carlo Messina, Valentina Massa, Mario Giuliano, Claudia Trojanello, Antonella Lucia Marretta, Fortunato Ciardiello, Antonio Avallone, Marianna Tortora, Ilaria Zampiva, Alessia Cavo, Floriana Morgillo, Andrea Sbrana, Piera Federico, Maria Grazia Vitale, Sandro Pignata, Antonia Silvestri, Paola Taveggia, Sara Merler, Paolo A. Ascierto, Michelino De Laurentiis, Ottaviano, Margaret, Curvietto, Marcello, Rescigno, Pasquale, Tortora, Marianna, Palmieri, Giovannella, Giannarelli, Diana, Aieta, Michele, Assalone, Pasquale, Attademo, Laura, Avallone, Antonio, Bloise, Francesco, Bosso, Davide, Borzillo, Valentina, Buono, Giuseppe, Calderoni, Giuseppe, Caputo, Francesca, Cartenì, Giacomo, Cavallero, Diletta, Cavo, Alessia, Ciardiello, Fortunato, Conca, Raffaele, Conteduca, Vincenza, De Falco, Stefano, De Felice, Marco, De Laurentiis, Michelino, De Placido, Pietro, De Placido, Sabino, De Santo, Irene, De Stefano, Alfonso, Della Corte, Carminia Maria, Di Franco, Rossella, Di Lauro, Vincenzo, Fabbrocini, Antonietta, Federico, Piera, Festino, Lucia, Giordano, Pasqualina, Giuliano, Mario, Gridelli, Cesare, Grimaldi, Antonio Maria, Lia, Michela, Marretta, Antonella Lucia, Massa, Valentina, Mennitto, Alessia, Merler, Sara, Merz, Valeria, Messina, Carlo, Messina, Marco, Milano, Monica, Minisini, Alessandro Marco, Montesarchio, Vincenzo, Morabito, Alessandro, Morgillo, Floriana, Mucci, Brigitta, Nappi, Lucia, Napolitano, Fabiana, Paciolla, Immacolata, Pagliuca, Martina, Palmieri, Giuseppe, Parola, Sara, Pepe, Stefano, Petrillo, Angelica, Piantedosi, Francovito, Piccin, Luisa, Picozzi, Fernanda, Pietroluongo, Erica, Pignata, Sandro, Prati, Veronica, Riccio, Vittorio, Rosanova, Mario, Rossi, Alice, Russo, Anna, Salati, Massimiliano, Santabarbara, Giuseppe, Sbrana, Andrea, Simeone, Ester, Silvestri, Antonia, Spada, Massimiliano, Tarantino, Paolo, Taveggia, Paola, Tomei, Federica, Vincenzo, Tortora, Trapani, Dario, Trojanello, Claudia, Vanella, Vito, Vari, Sabrina, Ventriglia, Jole, Vitale, Maria Grazia, Vitiello, Fabiana, Vivaldi, Caterina, von Arx, Claudia, Zacchi, Francesca, Zampiva, Ilaria, Zivi, Andrea, Daniele, Bruno, Ascierto, Paolo Antonio, Ottaviano, M., Curvietto, M., Rescigno, P., Tortora, M., Palmieri, G., Giannarelli, D., Aieta, M., Assalone, P., Attademo, L., Avallone, A., Bloise, F., Bosso, D., Borzillo, V., Buono, G., Calderoni, G., Caputo, F., Carteni, G., Cavallero, D., Cavo, A., Ciardiello, F., Conca, R., Conteduca, V., De Falco, S., De Felice, M., De Laurentiis, M., De Placido, P., De Placido, S., De Santo, I., De Stefano, A., Della Corte, C. M., Di Franco, R., Di Lauro, V., Fabbrocini, A., Federico, P., Festino, L., Giordano, P., Giuliano, M., Gridelli, C., Grimaldi, A. M., Lia, M., Marretta, A. L., Massa, V., Mennitto, A., Merler, S., Merz, V., Messina, C., Messina, M., Milano, M., Minisini, A. M., Montesarchio, V., Morabito, A., Morgillo, F., Mucci, B., Nappi, L., Napolitano, F., Paciolla, I., Pagliuca, M., Parola, S., Pepe, S., Petrillo, A., Piantedosi, F., Piccin, L., Picozzi, F., Pietroluongo, E., Pignata, S., Prati, V., Riccio, V., Rosanova, M., Rossi, A., Russo, A., Salati, M., Santabarbara, G., Sbrana, A., Simeone, E., Silvestri, A., Spada, M., Tarantino, P., Taveggia, P., Tomei, F., Vincenzo, T., Trapani, D., Trojanello, C., Vanella, V., Vari, S., Ventriglia, J., Vitale, M. G., Vitiello, F., Vivaldi, C., Von Arx, C., Zacchi, F., Zampiva, I., Zivi, A., Daniele, B., and Ascierto, P. A.
- Subjects
Male ,Cancer Research ,Immune checkpoint inhibitors ,Programmed Cell Death 1 Receptor ,Practice Patterns ,Medical Oncology ,B7-H1 Antigen ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Drug Prescription ,Neoplasms ,Surveys and Questionnaires ,Pandemic ,Prevalence ,Surveys and Questionnaire ,Infection control ,Immunology and Allergy ,CTLA-4 Antigen ,030212 general & internal medicine ,Viral ,Practice Patterns, Physicians' ,RC254-282 ,Clinical/Translational Cancer Immunotherapy ,Oncologists ,Geography ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,antineoplastic protocols ,Immunological ,Oncology ,Italy ,030220 oncology & carcinogenesis ,Molecular Medicine ,Female ,immunotherapy ,Coronavirus Infections ,Human ,healthcare economics and organizations ,Adult ,Telemedicine ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Pneumonia, Viral ,Immunology ,Antineoplastic Agents ,lung neoplasms ,Drug Prescriptions ,Time-to-Treatment ,03 medical and health sciences ,Betacoronavirus ,medicine ,melanoma ,COVID-19 ,Humans ,Infection Control ,Pandemics ,SARS-CoV-2 ,Medical prescription ,Pharmacology ,Physicians' ,Betacoronaviru ,Coronavirus Infection ,Cancer ,Outbreak ,Pneumonia ,medicine.disease ,lung neoplasm ,antineoplastic protocol ,Family medicine ,healthcare economics and organization ,Oncologist ,Neoplasm - Abstract
BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region.MethodsThis survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2–positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher’s exact tests for dichotomous answers and χ2 test for trends relative to the questions with 3 or more options.ResultsThis is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2–positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients’ planned treatment approach). The results from responders in Campania did not differ significantly from the national ones.ConclusionOur study highlights the efforts of Italian oncologists to maintain high standards of care for CPs treated with ICIs, regardless the regional prevalence of COVID-19, suggesting the adoption of similar solutions. Research on patients treated with ICIs and experiencing COVID-19 will clarify the safety profile to continue the treatments, thus informing on the most appropriate clinical conducts.
- Published
- 2020
16. Valorization of Olive Mill Wastewater by Membrane Processes to Recover Natural Antioxidant Compounds for Cosmeceutical and Nutraceutical Applications or Functional Foods
- Author
-
Alberto Alfano, F. Ferrara, Rosario Finamore, Luisana Corsuto, Maria Savarese, Giuseppe Santabarbara, Chiara Schiraldi, Mario De Rosa, Salvatore Falco, Alfano, A., Corsuto, L., Finamore, R., Savarese, M., Ferrara, F., Falco, S., Santabarbara, G., De Rosa, M., and Schiraldi, C.
- Subjects
0301 basic medicine ,Polyphenol ,Ultrafiltration membranes ,Antioxidant ,Physiology ,olive mill wastewaters ,polyphenols ,natural antioxidant ,functional food ,ultrafiltration membranes ,nano-filtration membranes ,cell culture ,scratch assays ,medicine.medical_treatment ,Clinical Biochemistry ,0211 other engineering and technologies ,02 engineering and technology ,Biochemistry ,Article ,Natural antioxidant ,03 medical and health sciences ,Nutraceutical ,Functional food ,Scratch assay ,medicine ,Food science ,Molecular Biology ,Carotenoid ,chemistry.chemical_classification ,Olive mill wastewater ,021110 strategic, defence & security studies ,Chemistry ,lcsh:RM1-950 ,food and beverages ,Cell Biology ,030104 developmental biology ,lcsh:Therapeutics. Pharmacology ,Wastewater ,Nanofiltration ,Cell culture ,Nano-filtration membrane ,Cosmeceutical - Abstract
Olive oil boasts numerous health benefits due to the high content of the monounsaturated fatty acid (MUFA) and functional bioactives including tocopherols, carotenoids, phospholipids, and polyphenolics with multiple biological activities. Polyphenolic components present antioxidant properties by scavenging free radicals and eliminating metabolic byproducts of metabolism. The objective of this research project was to recover the biologically active components rich in polyphenols, which include treatment of olive oil mills wastewater, and, at the same time, to remove the pollutant waste component resulting from the olive oil manufacturing processes. With specific focus on using technologies based on the application of ultra and nanofiltration membranes, the polyphenols fraction was extracted after an initial flocculation step. The nano-filtration permeate showed a reduction of about 95% of the organic load. The polyphenols recovery after two filtration steps was about 65% w/v. The nanofiltration retentate, dried using the spray dryer technique, was tested for cell viability after oxidative stress induction on human keratinocytes model in vitro and an improved cell reparation in the presence of this polyphenolic compound was demonstrated in scratch assays assisted through time lapse video-microscopy. The polyphenols recovered from these treatments may be suitable ingredients in cosmeceuticals and possibly nutraceutical preparations or functional foods.
- Published
- 2018
- Full Text
- View/download PDF
17. Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report
- Author
-
Filippo Venturini, Vincenzo Ricci, Alessio Fabozzi, Morena Fasano, Floriana Morgillo, Giuseppe Santabarbara, Flavia Cantile, Fortunato Ciardiello, Teresa Fabozzi, Ferdinando De Vita, Guido Giordano, Gaetano Aurilio, Fasano, M, Fabozzi, A, Giordano, G, Venturini, F, Aurilio, G, Cantile, F, Fabozzi, T, Ricci, V, Santabarbara, G, Morgillo, Floriana, Ciardiello, Fortunato, and DE VITA, Ferdinando
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,medicine.medical_treatment ,Rectum ,colorectal cancer ,complete response ,Capecitabine ,03 medical and health sciences ,0302 clinical medicine ,frail elderly patient ,Internal medicine ,medicine ,Complete response ,Chemotherapy ,business.industry ,capecitabine ,Cancer ,Articles ,medicine.disease ,digestive system diseases ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,advanced disease ,Adenocarcinoma ,030211 gastroenterology & hepatology ,Complication ,business ,medicine.drug - Abstract
The clinical management of frail, elderly patients affected by colorectal cancer (CRC) remains a subject of debate. The present study reports the case of an elderly man with metastatic CRC (mCRC) who was successfully treated with capecitabine. The patient survived for 29 months, thus highlighting its potential activity in terms of obtaining a complete response and high efficacy. A 77-year-old man presented with adenocarcinoma of the rectum with multiple and synchronous liver metastases, in addition to several comorbidities. The patient received single-agent capecitabine chemotherapy (825 mg/mq twice a day) on days 1–14 of a 21-day cycle. Following 12 cycles of well-tolerated therapy, a computed tomography scan revealed a complete response with no evidence of liver metastases. An overall survival of 29 months was documented, and the patient eventually succumbed to a diabetes-related complication. In compromised patients with mCRC, reduced-dose capecitabine is an excellent therapeutic option due to its positive safety profile, activity and efficacy.
- Published
- 2017
18. Current status of targeted therapies in advanced gastric Cancer
- Author
-
Fortunato Ciardiello, Nicola Silvestris, Giuseppe Santabarbara, Gennaro Galizia, Sabrina Rossetti, Ferdinando De Vita, Giuseppe Colucci, Francesco Giuliani, Antonio Pizzolorusso, Michele Orditura, DE VITA, Ferdinando, Giuliani, F, Silvestris, N, Rossetti, S, Pizzolorusso, A, Santabarbara, G, Galizia, Gennaro, Colucci, G, Ciardiello, Fortunato, and Orditura, Michele
- Subjects
Vascular Endothelial Growth Factor A ,Pharmacology ,Oncology ,medicine.medical_specialty ,Chemotherapy ,Bevacizumab ,Cetuximab ,business.industry ,medicine.medical_treatment ,Standard treatment ,Clinical Biochemistry ,Receptor Protein-Tyrosine Kinases ,Cancer ,Cell cycle ,medicine.disease ,Stomach Neoplasms ,Trastuzumab ,Internal medicine ,Drug Discovery ,Humans ,Molecular Medicine ,Medicine ,business ,medicine.drug ,EGFR inhibitors - Abstract
In metastatic gastric cancer, chemotherapy is the standard treatment because it prolongs survival when compared to best supportive care alone. However, even after the use of more effective regimens, the overall survival remains disappointing, justifying the need for new treatment options.Areas covered in this review include the most common molecular pathways, which have provided novel targets in gastric cancer therapy. These therapeutic strategies include EGFR inhibitors, anti-angiogenic agents, cell cycle inhibitors and apoptosis promoters.Several mAbs and kinase inhibitors, especially those targeting EGFR and VEGF/VEGFR, have already demonstrated promising activity in gastric cancer. The Phase III ToGA trial reported an increase in overall survival for patients with human EGF receptor (HER)2-positive gastric cancer treated with chemotherapy and trastuzumab compared to chemotherapy alone. This means that accurate HER2 testing in gastric cancer is necessary. Final data of ongoing trials with novel agents will be critical to further progress with this cancer.
- Published
- 2012
19. A rare case of extraovarian primary peritoneal carcinoma in a 72 year-old woman
- Author
-
Francesco Moccia, Marco Cimmino, V Trapani, G Romano, G Santabarbara, F. De Vita, Landino Fei, Moccia, F, Cimmino, M, Santabarbara, G, DE VITA, Ferdinando, Trapani, V, Romano, G, and Fei, Landino
- Subjects
Pathology ,medicine.medical_specialty ,endocrine system diseases ,business.industry ,Histology ,lcsh:Geriatrics ,Malignancy ,medicine.disease ,female genital diseases and pregnancy complications ,Serous fluid ,Peritoneal cavity ,lcsh:RC952-954.6 ,medicine.anatomical_structure ,Extraovarian primary peritoneal carcinoma ,Rare case ,Medicine ,Immunohistochemistry ,Epithelial ovarian cancer ,Geriatrics and Gerontology ,business ,Meeting abstract - Abstract
Background Extraovarian Primary Peritoneal Carcinoma (EOPPC) was first described by Swerdlow in 1959 [1]. Basically, EOPPC is a malignancy that spreads widely inside the peritoneal cavity involving mostly the omentum with minimal or no ovarian involvement. Most of the EOPPC cases reported have been of serous histology; histopathological, immunohistochemical, and clinical similarities have been observed between EOPPC and Epithelial Ovarian Cancer (EOC).
- Published
- 2010
20. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer
- Author
-
Giuseppe Catalano, Francesca Ferraraccio, Floriana Morgillo, E. Irlandese, Roberto Ruggiero, C. Belli, Morena Fasano, F. De Vita, Tina Cascone, Fortunato Ciardiello, Michele Orditura, E. Procaccini, F. Lo Schiavo, Giuliano Antoniol, Francesco Iovino, Gaetano Aurilio, M. R. Diadema, G Santabarbara, Iovino, Francesco, Ferraraccio, Franca, Orditura, Michele, Antoniol, G., Morgillo, Floriana, Cascone, T., Diadema, M. R., Aurilio, G., Santabarbara, G., Ruggiero, Roberto, Belli, C., Irlandese, E., Fasano, M., Ciardiello, Fortunato, Procaccini, Eugenio, LO SCHIAVO, F., Catalano, G., and DE VITA, Ferdinando
- Subjects
Oncology ,Adult ,Vascular Endothelial Growth Factor A ,Cancer Research ,medicine.medical_specialty ,Angiogenesis ,Estrogen receptor ,Breast Neoplasms ,Neovascularization ,Basal (phylogenetics) ,chemistry.chemical_compound ,Breast cancer ,Internal medicine ,medicine ,Humans ,Microvessel ,Aged ,Aged, 80 and over ,Neovascularization, Pathologic ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Neoplastic Cells, Circulating ,Immunohistochemistry ,Vascular endothelial growth factor ,chemistry ,Receptors, Estrogen ,Serum VEGF, ER-positive breast cancer, Microvessel ,Disease Progression ,Female ,medicine.symptom ,Tumor Suppressor Protein p53 ,business - Abstract
Vascular endothelial growth factor (VEGF) is a potent stimulator of angiogenesis, associated with unfavorable clinical characteristics in breast cancer. The aim of this study was to evaluate different angiogenic markers in endocrine-positive breast cancer patients. The authors analyzed serum and tumor samples from 71 patients with endocrine-positive operable primary breast cancer to determine the expression and the possible relationship between circulating serum VEGF levels, tumor VEGF expression, microvessel density (MVD), and other immunohistochemical parameters. Basal VEGF serum levels were significantly higher in breast cancer patients than in healthy controls. A significant correlation was observed between basal VEGF serum concentrations, microvessel density (p = 0.01) and p53 status (p = 0.004). Intratumoral VEGF expression was significantly associated with neoplastic embolization (p = 0.041) and circulating VEGF levels (p = 0.047). The results confirm that in primary endocrine-positive breast cancer serum VEGF levels are elevated and show a positive relationship with tumor VEGF and p53 overexpression.
- Published
- 2008
21. Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy.
- Author
-
Ciardiello D, Famiglietti V, Napolitano S, Esposito L, Normanno N, Avallone A, Latiano T, Maiello E, Pietrantonio F, Cremolini C, Santabarbara G, Pinto C, Troiani T, Martinelli E, Ciardiello F, and Martini G
- Abstract
The single-arm phase II CAVE mCRC trial evaluated the combination of cetuximab plus avelumab as rechallenge strategy in RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients, with clinical response to first-line anti-EGFR-based chemotherapy, who progressed and received a subsequent line of therapy. The correlation of skin toxicity (ST) and different clinico-molecular variables with overall survival (OS), progression-free survival (PFS) and response rate (RR) was assessed at univariate and multivariate analysis. A total of 33/77 (42.9%) patients experienced grade 2-3 ST and displayed median OS (mOS) of 17.8 months (CI 95%, 14.9-20.6); whereas 44/77 (57.1%) patients with grade 0-1 ST exhibited mOS of 8.2 months (CI 95%, 5.5-10.9), (hazard ratio (HR), 0.51; CI 95%, 0.29-0.89; p = 0.019). Median PFS (mPFS) was 4.6 months (CI 95%, 3.4-5.7) in patients with grade 2-3 ST, compared to patients with grade 0-1 ST with mPFS of 3.4 months (CI 95%, 2.7-4.1; HR, 0.49; CI 95%, 0.3-0.8; p = 0.004). Grade 2-3 ST (HR, 0.51; CI 95%, 0.29-0.89; p = 0.019) and RAS/BRAF/EGFR WT circulating tumor DNA (ctDNA) (HR, 0.50; CI 95%, 0.27-0.9; p = 0.019) had a statistically significant effect on OS at univariate analysis. At the multivariate analysis, RAS/BRAF/EGFR WT ctDNA status maintained statistical significance (HR, 0.49; CI 95%, 0.27-0.9; p = 0.023), whereas there was a trend towards ST grade 2-3 (HR, 0.54; CI 95%, 0.29-1.01; p = 0.054). Skin toxicity is a promising biomarker to identify patients with mCRC that could benefit of anti-EGFR rechallenge.
- Published
- 2021
- Full Text
- View/download PDF
22. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
- Author
-
Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, Ciardiello D, Terminiello M, Borrelli C, Vitiello PP, De Braud F, Morano F, Avallone A, Normanno N, Nappi A, Maiello E, Latiano T, Falcone A, Cremolini C, Rossini D, Santabarbara G, Pinto C, Santini D, Cardone C, Zanaletti N, Di Liello A, Renato D, Esposito L, Marrone F, and Ciardiello F
- Subjects
- Antibodies, Monoclonal, Humanized adverse effects, Cetuximab, Female, Humans, Male, Middle Aged, Proto-Oncogene Proteins p21(ras) genetics, Antineoplastic Combined Chemotherapy Protocols adverse effects, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology
- Abstract
Importance: Rechallenge therapy with anti-epidermal growth factor receptor (EGFR) drugs has been suggested in patients with chemo-refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC) after initial response to anti-EGFR-based first-line treatment. The association of treatment with cetuximab plus avelumab with overall survival (OS) may be worthy of investigation in this setting., Objective: To assess the efficacy and safety of cetuximab rechallenge therapy plus avelumab., Design, Setting, and Participants: This single-arm, multicenter phase 2 trial enrolled patients from August 2018 to February 2020. Eligible patients with RAS WT mCRC had a complete or partial response to first-line chemotherapy plus anti-EGFR drugs, developed acquired resistance, and failed second-line therapy. Baseline circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S492R mutation analysis was done., Interventions: Patients received avelumab (10 mg/kg every 2 weeks) and cetuximab (400 mg/m2 and, subsequently, 250 mg/m2 weekly) until disease progression or unacceptable toxic effects., Main Outcomes and Measures: The primary end point was OS. Secondary end points were progression-free survival (PFS), overall response rate (ORR), and safety., Results: Seventy-seven patients were enrolled (42 men, 35 women; median age, 63 years); 71 had microsatellite stable tumors (MSS), 3 microsatellite instability-high tumors (MSI-H), 3 unknown. The study met the primary end point, with median OS (mOS) of 11.6 months (95% CI, 8.4-14.8 months). Median PFS (mPFS) was 3.6 months (95% CI, 3.2-4.1 months). Common grade-3 adverse events were cutaneous eruption, 11 (14%), and diarrhea, 3 (4%). For 67 of 77 (87%) patients, baseline analysis of plasma circulating tumor DNA (ctDNA) for KRAS, NRAS, BRAF, and EGFR-S492R variations was feasible. Forty-eight patients had WT disease, whereas 19 had mutations. Patients with RAS/BRAF WT ctDNA had mOS of 17.3 months (95% CI, 12.5-22.0 months) compared with 10.4 months (95% CI, 7.2-13.6 months) in patients with mutated ctDNA (hazard ratio [HR], 0.49; 95% CI, 0.27-0.90; P = .02). The mPFS was 4.1 months (95% CI, 2.9-5.2 months) in RAS/BRAF WT patients compared with 3.0 months (95% CI, 2.6-3.5 months) in patients with mutated ctDNA (HR, 0.42; 95% CI, 0.23-0.75; P = .004)., Conclusions and Relevance: The findings of this single-arm phase 2 trial suggest that cetuximab plus avelumab is an active, well tolerated rechallenge therapy in RAS WT mCRC. Plasma ctDNA analysis before treatment may allow selection of patients who could benefit., Trial Registration: ClinicalTrials.gov Identifier: NCT04561336.
- Published
- 2021
- Full Text
- View/download PDF
23. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
- Author
-
Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Cartenì G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Palmieri G, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, and Ascierto PA
- Subjects
- Adult, Antineoplastic Agents, Immunological adverse effects, B7-H1 Antigen antagonists & inhibitors, B7-H1 Antigen immunology, Betacoronavirus pathogenicity, COVID-19, CTLA-4 Antigen antagonists & inhibitors, CTLA-4 Antigen immunology, Coronavirus Infections immunology, Coronavirus Infections prevention & control, Coronavirus Infections transmission, Drug Prescriptions statistics & numerical data, Female, Geography, Humans, Infection Control standards, Italy epidemiology, Male, Medical Oncology standards, Neoplasms immunology, Oncologists statistics & numerical data, Pandemics prevention & control, Pneumonia, Viral immunology, Pneumonia, Viral prevention & control, Pneumonia, Viral transmission, Practice Patterns, Physicians' standards, Practice Patterns, Physicians' statistics & numerical data, Prevalence, Programmed Cell Death 1 Receptor antagonists & inhibitors, Programmed Cell Death 1 Receptor immunology, SARS-CoV-2, Surveys and Questionnaires statistics & numerical data, Time-to-Treatment, Antineoplastic Agents, Immunological administration & dosage, Betacoronavirus immunology, Coronavirus Infections epidemiology, Medical Oncology statistics & numerical data, Neoplasms drug therapy, Pneumonia, Viral epidemiology
- Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region., Methods: This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ
2 test for trends relative to the questions with 3 or more options., Results: This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones., Conclusion: Our study highlights the efforts of Italian oncologists to maintain high standards of care for CPs treated with ICIs, regardless the regional prevalence of COVID-19, suggesting the adoption of similar solutions. Research on patients treated with ICIs and experiencing COVID-19 will clarify the safety profile to continue the treatments, thus informing on the most appropriate clinical conducts., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2020
- Full Text
- View/download PDF
24. Valorization of Olive Mill Wastewater by Membrane Processes to Recover Natural Antioxidant Compounds for Cosmeceutical and Nutraceutical Applications or Functional Foods.
- Author
-
Alfano A, Corsuto L, Finamore R, Savarese M, Ferrara F, Falco S, Santabarbara G, De Rosa M, and Schiraldi C
- Abstract
Olive oil boasts numerous health benefits due to the high content of the monounsaturated fatty acid (MUFA) and functional bioactives including tocopherols, carotenoids, phospholipids, and polyphenolics with multiple biological activities. Polyphenolic components present antioxidant properties by scavenging free radicals and eliminating metabolic byproducts of metabolism. The objective of this research project was to recover the biologically active components rich in polyphenols, which include treatment of olive oil mills wastewater, and, at the same time, to remove the pollutant waste component resulting from the olive oil manufacturing processes. With specific focus on using technologies based on the application of ultra and nanofiltration membranes, the polyphenols fraction was extracted after an initial flocculation step. The nano-filtration permeate showed a reduction of about 95% of the organic load. The polyphenols recovery after two filtration steps was about 65% w / v . The nanofiltration retentate, dried using the spray dryer technique, was tested for cell viability after oxidative stress induction on human keratinocytes model in vitro and an improved cell reparation in the presence of this polyphenolic compound was demonstrated in scratch assays assisted through time lapse video-microscopy. The polyphenols recovered from these treatments may be suitable ingredients in cosmeceuticals and possibly nutraceutical preparations or functional foods.
- Published
- 2018
- Full Text
- View/download PDF
25. Selumetinib for the treatment of non-small cell lung cancer.
- Author
-
Casaluce F, Sgambato A, Maione P, Sacco PC, Santabarbara G, and Gridelli C
- Subjects
- Animals, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Benzimidazoles pharmacology, Carcinoma, Non-Small-Cell Lung genetics, Docetaxel, Humans, Lung Neoplasms genetics, Mutation, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Proto-Oncogene Proteins p21(ras) genetics, Taxoids administration & dosage, Benzimidazoles therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
Introduction: KRAS is the most frequently mutated oncogene in NSCLC, occurring in around a third of patients. However, this largest genomically defined subgroup of lung cancer patients seem to remain 'undruggable', with any effective targeted therapy approved at the moment. The prognostic and predictive power and thus the clinical utility of KRAS oncogenic mutations in lung cancer are highly debated issues, not supportive of KRAS testing in clinical practice of NSCLC therapy. Areas covered: A phase II trial in KRAS-mutant NSCLC had shown significant improvements in PFS and ORR in patients treated with selumetinib plus docetaxel compared to docetaxel alone. Disappointing data emerged from the next phase III trial in which the addition of selumetinib to docetaxel in patients with advanced KRAS mutant lung cancer did not improve survival or show clinical benefit. Expert opinion: Promising strategies against this common mutation are under evaluation in clinical trials. Combination therapies represent a potential approach for overcoming this complex pathway and potentiating the activity of other antitumor agents, by simultaneous inhibition of the RAS-RAF-MEK-MAPK pathway. Identifying predictive biomarkers, and delineating de novo and acquired resistance mechanisms are essential for future clinical development of MEK inhibitors.
- Published
- 2017
- Full Text
- View/download PDF
26. The safety of second-line treatment options for non-small cell lung cancer.
- Author
-
Rossi A, Maione P, Santabarbara G, Sacco PC, Casaluce F, Sgambato A, Barzelloni ML, Palazzolo G, and Gridelli C
- Subjects
- Angiogenesis Inhibitors administration & dosage, Angiogenesis Inhibitors adverse effects, Angiogenesis Inhibitors therapeutic use, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Carcinoma, Non-Small-Cell Lung pathology, ErbB Receptors antagonists & inhibitors, Humans, Immunotherapy methods, Lung Neoplasms pathology, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors therapeutic use, Quality of Life, Survival, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
Introduction: Non-small-cell lung cancer (NSCLC) patients after first-line therapy ultimately suffer progression. At this time, many patients still have a good performance status and can be considered for further active treatment. Two chemotherapeutic agents, docetaxel and pemetrexed (only in non-squamous histology), and the biological drug anti-epidermal growth factor receptor (EGFR) erlotinib, were approved for clinical use in the second-line treatment of NSCLC patients. In the last few years further new second-line therapies have become available in the clinical practice. Areas covered: This review will discuss the adverse events of the pivotal trials ledding to the approval of second-line therapies for the treatment of not oncogene-addicted NSCLC patients. Expert opinion: In recent years, new second-line options for NSCLC are: the anti-EGFR, afatinib (only in squamous NSCLC); the anti-angiogenics, nintedanib (only in lung adenocarcinoma) and ramucirumab, in combination with docetaxel; the immunotherapeutics, nivolumab, pembrolizumab, and atezolizumab. In the second-line approach, the main endpoint of treatment should always be survival, but with great respect for symptoms palliation and preserving patients' quality of life. Therefore, differing toxicity profiles of the available therapeutic options are often a deciding factor in second-line setting for NSCLC.
- Published
- 2017
- Full Text
- View/download PDF
27. Developments in pharmacotherapy for treating metastatic non-small cell lung cancer.
- Author
-
Rossi A, Sacco PC, Santabarbara G, Sgambato A, Casaluce F, Palazzolo G, Maione P, and Gridelli C
- Subjects
- Adenocarcinoma drug therapy, Anaplastic Lymphoma Kinase, Antineoplastic Agents therapeutic use, Carcinoma, Squamous Cell drug therapy, ErbB Receptors antagonists & inhibitors, Humans, Randomized Controlled Trials as Topic, Receptor Protein-Tyrosine Kinases antagonists & inhibitors, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Protein Kinase Inhibitors therapeutic use
- Abstract
Introduction: Most patients with non-small cell lung (NSCLC), including squamous cell carcinoma, adenocarcinoma and large cell carcinoma, have advanced disease at diagnosis and systemic therapy is the standard-of-care. About 20% of Caucasian patients are affected by an oncogene-addicted advanced NSCLC for which correspondent inhibitors are available. Areas covered: The main state-of-the-art synthetic anticancer drugs in the groups of chemotherapeutics, epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors for NSCLC treatment, are reviewed and discussed from phase III randomized practice-changing trials onwards. A structured search of bibliographic databases for peer-reviewed research literature and of main meetings using a focused review question was undertaken. Expert opinion: The survival of NSCLC patients is increasing, regardless of the presence or not of a specific target, due to the availability of new generation drugs. The continuous deep knowledge of the mechanisms of NSCLC development and the constant research into new drugs should lead to the discovery of new potential targets and the synthesis of corresponding inhibitors to improve the outcomes of each subgroup of patients in order to control the disease in a constantly growing percentage of patients.
- Published
- 2017
- Full Text
- View/download PDF
28. Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report.
- Author
-
Fasano M, Fabozzi A, Giordano G, Venturini F, Aurilio G, Cantile F, Fabozzi T, Ricci V, Santabarbara G, Morgillo F, Ciardiello F, and De Vita F
- Abstract
The clinical management of frail, elderly patients affected by colorectal cancer (CRC) remains a subject of debate. The present study reports the case of an elderly man with metastatic CRC (mCRC) who was successfully treated with capecitabine. The patient survived for 29 months, thus highlighting its potential activity in terms of obtaining a complete response and high efficacy. A 77-year-old man presented with adenocarcinoma of the rectum with multiple and synchronous liver metastases, in addition to several comorbidities. The patient received single-agent capecitabine chemotherapy (825 mg/mq twice a day) on days 1-14 of a 21-day cycle. Following 12 cycles of well-tolerated therapy, a computed tomography scan revealed a complete response with no evidence of liver metastases. An overall survival of 29 months was documented, and the patient eventually succumbed to a diabetes-related complication. In compromised patients with mCRC, reduced-dose capecitabine is an excellent therapeutic option due to its positive safety profile, activity and efficacy.
- Published
- 2017
- Full Text
- View/download PDF
29. The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer.
- Author
-
Maione P, Sgambato A, Casaluce F, Sacco PC, Santabarbara G, Rossi A, and Gridelli C
- Subjects
- Angiogenesis Inhibitors chemistry, Angiogenesis Inhibitors pharmacology, Antibodies, Monoclonal chemistry, Antibodies, Monoclonal, Humanized, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Carcinoma, Non-Small-Cell Lung pathology, Cell Proliferation drug effects, Humans, Lung Neoplasms pathology, Neovascularization, Pathologic pathology, Ramucirumab, Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Neovascularization, Pathologic drug therapy
- Abstract
Angiogenesis is one of the most important phenomena sustaining tumor development and metastatization, including for non small cell lung cancer (NSCLC). A dominant role in angiogenesis is played by the vascular endothelial growth factor (VEGF) and its signaling pathway. Ramucirumab, is a fully human immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of the VEGF receptor-2 (VEGFR-2) with high specificity and affinity blocking the interaction of VEGFR-2 and VEGF ligands, thus inhibiting their signaling pathways and the consequential endothelial proliferation and migration. A recent phase III randomized trial named REVEL, demonstrated the efficacy of ramucirumab in combination with docetaxel as second line treatment of advanced NSCLC, leading to its FDA and EMA approval in this clinical setting. In the REVEL trial advanced NSCLC patients whose disease had progressed after first line platinum-based chemotherapy, were administered ramucirumab plus docetaxel or placebo plus docetaxel. More than 1,250 patients were treated and patients randomized to the treatment with ramucirumab plus docetaxel showed a significant longer median overall survival compared to those randomized to chemotherapy only. Ramucirumab is the first antiangiogenetic agent approved in the treatment both of squamous and non squamous NSCLC. In fact, it is not associated with increased risk of respiratory bleeding in the squamous histology, and also has demonstrated efficacy in both histology types. The role of ramucirumab, already cleared in the second-line treatment of advanced NSCLC, needs to be clarified further and is currently being explored also in the first-line treatment of advanced NSCLC., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)
- Published
- 2017
- Full Text
- View/download PDF
30. The role of pembrolizumab in the treatment of advanced non-small cell lung cancer.
- Author
-
Santabarbara G, Maione P, Rossi A, Palazzolo G, and Gridelli C
- Abstract
Lung cancer is the leading cause of death cancer related worldwide. The standard therapies have unmet medical needs both due to the limited activity and relevant toxicity of platinum-based chemotherapy and to the low frequency of specific alterations required to use targeted therapies. Immune checkpoint inhibition due to restoring the immune system's capacity to eradicate tumors is undergoing in extensive investigation in non-small cell lung cancer (NSCLC) as a new treatment approach. Programmed cell death protein-1 (PD-1) and its ligand, programmed cell death-ligand 1 (PD-L1) have recently led to significantly and durable improvements in the clinical outcome of several kind of tumors including lung cancer. Pembrolizumab, approved by the U.S. FDA for the treatment of advanced NSCLC progressed after other therapies and with expression of PD-L1, has demonstrated durable response and prolonged overall survival (OS) especially in patients with high PD-L1 expression. Further investigation are needed to improve treatment outcomes through combination of immunotherapy or combined with other targeted therapies.
- Published
- 2016
- Full Text
- View/download PDF
31. Optimal drugs for second-line treatment of patients with small-cell lung cancer.
- Author
-
Rossi A, Sacco PC, Sgambato A, Casaluce F, Santabarbara G, Palazzolo G, Maione P, and Gridelli C
- Subjects
- Anthracyclines therapeutic use, Antibodies, Monoclonal therapeutic use, Humans, Immunotherapy, Ipilimumab, Lung Neoplasms immunology, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local immunology, Nivolumab, Randomized Controlled Trials as Topic, Small Cell Lung Carcinoma immunology, Topotecan therapeutic use, Antineoplastic Agents therapeutic use, Lung Neoplasms drug therapy, Small Cell Lung Carcinoma drug therapy
- Abstract
Introduction: Despite the high response rate to chemotherapy, there have been few advances in the treatment of small-cell lung cancer (SCLC) in the last decades. The state-of-the-art second-line therapy and future research developments in relapsed SCLC are reviewed., Areas Covered: There are no optimal drugs for second-line treatment of recurrent SCLC but only agents registered for this use. Topotecan remains the standard-of-care for the treatment of second-line platinum-sensitive SCLC patients worldwide, while amrubicin is another option, but registered only in Japan. To date, no targeted agents reporting interesting results in second-line SCLC treatment are available. The next-generation DNA sequencing should discover somatic gene alterations and their roles in SCLC to help in selecting patients who could benefit from a targeted agent. Two immunotherapeutics, ipilimumab and nivolumab, have shown promising preliminary results and are being investigated in ongoing trials., Expert Opinion: Second-line treatment is not an option for most SCLC patients. Given the evidence up to now, the potentials for immuno-oncology in SCLC are high. The hope is that these expectations are met, and that all drugs being developed will offer new and improved treatment options for SCLC patients.
- Published
- 2016
- Full Text
- View/download PDF
32. Pharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapy.
- Author
-
Santabarbara G, Maione P, Rossi A, and Gridelli C
- Subjects
- Ear Diseases etiology, Ear Diseases prevention & control, Humans, Nausea chemically induced, Nausea prevention & control, Neurotoxicity Syndromes etiology, Neurotoxicity Syndromes prevention & control, Quality of Life, Risk Factors, Vomiting chemically induced, Vomiting prevention & control, Antineoplastic Agents adverse effects, Cisplatin adverse effects
- Abstract
Introduction: Cisplatin is widely used in the treatment of several tumors such as lung, ovarian and testicular cancer with different degrees of effectiveness, and its use is burdened by some side effects., Areas Covered: This review includes the most important cisplatin side effects such as neurotoxicity, nephrotoxicity, ototoxicity, nausea and vomiting. They can affect patient's quality of life and lead to treatment interruptions with effectiveness reduction., Expert Opinion: Specific mechanisms of cisplatin-induced DNA damage and production of reactive oxygen species are the main ones responsible of toxicity. Several clinical approaches have been developed to reduce or prevent these effects with very promising results. The greatest potential for clinical practice is for amifostine, vitamin E, silymarin and NK-1 receptor antagonists.
- Published
- 2016
- Full Text
- View/download PDF
33. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
- Author
-
Rossi E, Sgambato A, De Chiara G, Casaluce F, Losanno T, Sacco PC, Santabarbara G, and Gridelli C
- Subjects
- Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized pharmacology, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, B7-H1 Antigen antagonists & inhibitors, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung immunology, Carcinoma, Non-Small-Cell Lung pathology, Endocrine System Diseases diagnosis, Endocrine System Diseases therapy, Humans, Immunotherapy methods, Lung Neoplasms drug therapy, Lung Neoplasms immunology, Lung Neoplasms pathology, Nivolumab, Programmed Cell Death 1 Receptor antagonists & inhibitors, Antineoplastic Agents adverse effects, Endocrine System Diseases chemically induced, Immunotherapy adverse effects
- Abstract
The advent of immunotherapy has recently expanded the therapeutic options in advanced non-small cell lung cancer (NSCLC). In these patients, the recent efficacy demonstration of antibodies against immune checkpoints: the anti-programmed death-1 (PD-1) and anti-programmed death ligand-1 (PD-L1), has led to approval of nivolumab and pembrolizumab (anti-PD-1) in the treatment of advanced NSCLC. The mechanism of action of checkpoint inhibitors explains the development of autoimmune diseases as a side-effect of these medications. Among these, a spectrum of endocrine disorders has been also reported. This manuscript focuses particularly on endocrine disorders induced by immuno-checkpoint inhibitors employed in NSCLC, in order to suggest the strategies for their diagnosis and effective management.
- Published
- 2016
- Full Text
- View/download PDF
34. Overcoming Resistance to EGFR Inhibitors in NSCLC.
- Author
-
Maione P, Sacco PC, Casaluce F, Sgambato A, Santabarbara G, Rossi A, and Gridelli C
- Subjects
- Disease-Free Survival, Humans, Mutation, Carcinoma, Non-Small-Cell Lung drug therapy, ErbB Receptors antagonists & inhibitors, Lung Neoplasms drug therapy, Protein Kinase Inhibitors therapeutic use
- Abstract
Background: The clarification of several molecular pathways underlying the tumorigenesis has led to the development of several targeted drugs that have substantially improved the treatment of Non-Small-Cell Lung Cancer (NSCLC). The Epidermal Growth Factor Receptor (EGFR) is the target of several Tyrosine-Kinase Inhibitors (TKIs), some of them approved for treatment and others currently in clinical development. EGFR-TKIs markedly improve progression-free survival of patients with advanced NSCLC with EGFR mutations compared with chemotherapy., Methods: We undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question., Results: Although first- and second-generation agents offer in target population (with EGFR mutations) a substantial improvement of outcomes compared with standard chemotherapy, unfortunately, drug resistance develops after initial benefit, through a variety of mechanisms. Novel- (third) generation EGFR inhibitors have a selective mechanism of action and are currently in advanced clinical development, producing encouraging results in patients with acquired resistance to previous generation agents., Conclusion: The search for new drugs or strategies to overcome the TKI resistance in patients with EGFR mutations is to be considered a priority for the improvement of outcomes in the treatment of advanced NSCLC, and third-generation EGFR inhibitors are the most promising approach to the issue.
- Published
- 2016
- Full Text
- View/download PDF
35. Current status of targeted therapies in advanced gastric cancer.
- Author
-
De Vita F, Giuliani F, Silvestris N, Rossetti S, Pizzolorusso A, Santabarbara G, Galizia G, Colucci G, Ciardiello F, and Orditura M
- Subjects
- Humans, Receptor Protein-Tyrosine Kinases antagonists & inhibitors, Stomach Neoplasms drug therapy, Vascular Endothelial Growth Factor A antagonists & inhibitors, Receptor Protein-Tyrosine Kinases metabolism, Stomach Neoplasms metabolism, Vascular Endothelial Growth Factor A metabolism
- Abstract
Introduction: In metastatic gastric cancer, chemotherapy is the standard treatment because it prolongs survival when compared to best supportive care alone. However, even after the use of more effective regimens, the overall survival remains disappointing, justifying the need for new treatment options., Areas Covered: Areas covered in this review include the most common molecular pathways, which have provided novel targets in gastric cancer therapy. These therapeutic strategies include EGFR inhibitors, anti-angiogenic agents, cell cycle inhibitors and apoptosis promoters., Expert Opinion: Several mAbs and kinase inhibitors, especially those targeting EGFR and VEGF/VEGFR, have already demonstrated promising activity in gastric cancer. The Phase III ToGA trial reported an increase in overall survival for patients with human EGF receptor (HER)2-positive gastric cancer treated with chemotherapy and trastuzumab compared to chemotherapy alone. This means that accurate HER2 testing in gastric cancer is necessary. Final data of ongoing trials with novel agents will be critical to further progress with this cancer.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.